Work

A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study

Year: 2017

Type: article

Abstract: Purpose: To compare the long-term survival outcomes and acute toxicity between locoregionally advanced nasopharyngeal carcinoma (NPC) patients who received either weekly or 3-weekly cisplatin during concurrent chemoradiotherapy (CCRT).Methods: Between November 2008 and August 2011, 241 biopsy-proved NPC patients receiving concurrent cisplatin with intensity modulated radiotherapy (IMRT) were included.90 patients treated with 4-7 weeks of 30-40 mg/m 2 cisplatin weekly were matched with 90 patients who received two or three cycles of 80 mg/m 2 cisplatin three-weekly by sex, age, T stage, N stage, Karnosky performance score (KPS).IMRT was presented to the nasopharyngeal gross target volume at 66-72 Gy/30-32 fractions and those involved neck area at 60-66 Gy/30-32 fractions.Results: The median follow-up time was 69 months (range, 2-91 months), and the 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) rates were 85.6% vs. 90.0%(P = 0.207), 85.6% vs. 92.6%(P = 0.152), 94.4% vs. 96.7%(P = 0.411), and 88.9% vs. 95.6%(P = 0.107) for the group treated weekly and 3-weekly cisplatin, respectively.No statistically significant survival differences were found between the two treatment groups in both univariate and multivariate analyses.The similar incidence of acute toxicities was observed between two groups.Conclusions: Concurrent cisplatin-based chemotherapy administered weekly or three-weekly in combination with IMRT leads to similar acute toxicities and long-term survival outcomes in locoregionally advanced NPC patients.

Source: Journal of Cancer

DOI: 10.7150/jca.21357